Repositorio Dspace

Listar por tema "Neoplasm Metastasis"

Listar por tema "Neoplasm Metastasis"

Ordenar por:Orden:Resultados:

  • Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients 
    Jiménez, Natalia; García-de-Herreros, Marta; Reig, Óscar; Marín-Aguilera, Mercedes; Aversa, Caterina; Ferrer-Mileo, Laura; García-Esteve, Samuel; Rodríguez-Carunchio, Leonardo; Trias, Isabel; Font, Albert; Rodríguez-Vida, Alejo; Climent, Miguel-Ángel; Cros, Sara; Chirivella, Isabel; Domenech, Montserrat; Figols, Mariona; Carles, Joan; Suárez, Cristina; Herrero-Rivera, Daniel; González-Billalabeitia, Enrique; Civico, Claudia; Sala-González, Nuria; de-Porras, Vicenc-Ruiz; Ribal, María-J; Prat, Aleix; Mellado, Begoña (ELSEVIER, 2024-08)
    BACKGROUND: Androgen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard therapies in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations in the tumor ...
  • Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer 
    Boegemann, Martin; Bennamoun, Mostefa; Dourthe, Louis-Marie; Encarnación-Navarro, Juan-Antonio; Hegele, Axel; Hellmis, Eva; Latorzeff, Igor; Leicht, Wolfgang; Oñate-Celdrán, Julián; Rosino-Sánchez, Antonio; Hanna, Krystelle; Lencart, Joana; Lukac, Martin; Schioppa, Claudio-A; Van-Sanden, Suzy; Kramer, Gero (BMC, 2025-07-01)
    BACKGROUND: We examined real-world outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with apalutamide plus androgen deprivation therapy (ADT). The current study, reflecting real-life ...
  • Genome-wide plasma DNA methylation features of metastatic prostate cancer 
    Wu, Anjui; Cremaschi, Paolo; Wetterskog, Daniel; Conteduca, Vincenza; Franceschini, Gian-Marco; Kleftogiannis, Dimitrios; Jayaram, Anuradha; Sandhu, Shahneen; Wong, Stephen-Q; Benelli, Matteo; Salvi, Samanta; Gurioli, Giorgia; Feber, Andrew; Pereira, Mariana-Buongermino; Wingate, Anna-María; González-Billalabeitia, Enrique; de-Giorgi, Ugo; Demichelis, Francesca; Lise, Stefano; Attard, Gerhardt (AMER SOC CLINICAL INVESTIGATION INC, 2020-04-01)
    Tumor DNA circulates in the plasma of cancer patients admixed with DNA from noncancerous cells. The genomic landscape of plasma DNA has been characterized in metastatic castration-resistant prostate cancer (mCRPC) but the ...
  • Multicenter Real-World Study: 432 Patients with Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer 
    Encarnación-Navarro, Juan-Antonio; Morillo-Macias, Virginia; Calbo, María-Borras; de-la-Fuente-Muñoz, Isabel; Lozano-Martínez, Antonio-José; García-Martínez, Vicente-Luis; Fernández-Fornos, Luis; Roche, Miriam-Guijarro; Rey, Osamah-Amr; García-Gómez, Raquel (MDPI, 2025-02-21)
    Background: The management of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved significantly in recent years due to the introduction of androgen receptor-targeted agents (ARTAs). When used alongside androgen ...
  • Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables 
    Ivars-Rubio, Alejandra; Yufera, Juan-Carlos; de-la-Morena, Pilar; Fernández-Sánchez, Ana; Navarro-Manzano, Esther; García-Garre, Elisa; García-Martínez, Elena; Marín-Zafra, Gema; Sánchez-Cánovas, Manuel; García-Torralba, Esmeralda; Ayala-de-la-Peña, Francisco (NATURE PORTFOLIO, 2019-11-18)
    The prognostic impact of neutrophil-lymphocyte ratio (NLR) in metastatic breast cancer (MBC) has been previously evaluated in early and metastatic mixed breast cancer cohorts or without considering other relevant prognostic ...
  • Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 
    Conteduca, Vincenza; Jayaram, Anuradha; Romero-Laorden, Nuria; Wetterskog, Daniel; Salvi, Samanta; Gurioli, Giorgia; Scarpi, Emanuela; Castro, Elena; Marín-Aguilera, Mercedes; Lolli, Cristian; Schepisi, Giuseppe; Maugeri, Antonio; Wingate, Anna; Farolfi, Alberto; Casadio, Valentina; Medina, Ana; Puente, Javier; Méndez-Vidal, María-José; Morales-Barrera, Rafael; Villa-Guzmán, José-C; Hernando, Susana; Rodríguez-Vida, Alejo; González-del-Alba, Aranzazu; Mellado, Begoña; González-Billalabeitia, Enrique; Olmos, David; Attard, Gerhardt; De-Giorgi, Ugo (ELSEVIER SCIENCE BV, 2019-03)
    Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is ...
  • Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study 
    Fernández, Ana; Salgado, Mercedes; García, Adelaida; Buxo, Elvira; Vera, Ruth; Adeva, Jorge; Jiménez-Fonseca, Paula; Quintero, Guillermo; Llorca, Cristina; Canabate, Mamen; Jesus-López, Luis; Muñoz, Andrés; Ramírez, Patricia; González, Paula; López, Carlos; Reboredo, Margarita; Gallardo, Elena; Sánchez-Cánovas, Manuel; Gallego, Javier; Guillén, Carmen; Ruiz-Miravet, Nuria; Navarro-Pérez, Víctor; de-la-Cámara, Juan; Ales-Díaz, Inmaculada; Pazo-Cid, Roberto-Antonio; Carmona-Bayonas, Alberto (BMC, 2018-11-29)
    BACKGROUND: Treatment with nab-paclitaxel plus gemcitabine increases survival in patients with metastatic pancreatic cancer. However, the assessment of treatment efficacy and safety in non-selected patients in a real-life ...
  • The NADPH oxidase NOX4 represses epithelial to amoeboid transition and efficient tumour dissemination 
    Crosas-Molist, E; Bertran, E; Rodríguez-Hernández, I; Herraiz, C; Cantelli, G; Fabra, A; Sanz-Moreno, V; Fabregat, I (NATURE PUBLISHING GROUP, 2017-05-25)
    Epithelial to mesenchymal transition is a common event during tumour dissemination. However, direct epithelial to amoeboid transition has not been characterized to date. Here we provide evidence that cells from hepatocellular ...
  • Tinzaparin for the prevention of thromboembolic events in ambulatory patients with metastatic colorectal cancer receiving first line treatment: a randomised, clinical trial design 
    Salgado, Mercedes; de-la-Camara-Gómez, Juan; García-Escobar, Ignacio; Álvarez-Llosa, Renata-Carola; González-Villarroel, Paula; Fernández-Garay, David; Pampols-Felip, Montse; Guillot-Morales, Mónica; Pelegrin-Mateo, Francisco-José; Jiménez-Orozco, Encarnación; Sastre, Javier; Martínez-de-Castro, Eva; Coma, Eva; Paris-Bouzas, Lorena; Ferrer-Pérez, Ana-Isabel; Momprade-Olive, Elisabet; Cousillas-Castineiras, Antia; Covela-Rua, Marta; Rojas, Maríam; Querol, Rosa; Díaz, Luis-Robles; Merino, Marta; Gil, Mireia; Sánchez-Cánovas, Manuel; Elias, Teresa; Marrupe-González, David; Sánchez-Gil, Belén; Carmona-Campos, Marta; García-Ferron, María; Soria, José-Manuel; Muñoz, Andrés (BMC, 2025-11-17)
    BACKGROUND: Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. CRC leads to increased activation of the clotting system. Since CRC patients present a higher rate of bleeding, careful evaluation ...
  • Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination 
    Martín-Martin, Natalia; García-Longarte, Saioa; Corres-Mendizabal, Jon; Lazcano, Uxue; Astobiza, Ianire; Bozal-Basterra, Laura; Herranz, Nicolas; van-Splunder, Hielke; Carlevaris, Onintza; Pujana-Vaquerizo, Mikel; Blasco, María-Teresa; Aransay, Ana-M; Rosino-Sánchez, Antonio; Tudela-Pallarés, Julián; Jiménez, Daniel; Martínez, Alberto; Salca, Andrei; Santos-Martin, Aida; Rey, Sofia; Ugalde-Olano, Aitziber; Gonzalo, David; Graupera, Mariona; Gomis, Roger-R; Mateo, Joaquín; Unda, Miguel; González-Billalabeitia, Enrique; Loizaga-Iriarte, Ana; Mendizabal, Isabel; Carracedo, Arkaitz (BMC, 2025-06-03)
    BACKGROUND: Metastatic hormone-naïve prostate cancer (mHNPC) is an infrequent form of this tumor type that is characterized by metastasis at the time of diagnosis and accounts for up to 50% of prostate cancer-related deaths. ...